Novo Nordisk in the expanding market of diabetes care
The Danish multinational offers an exciting growth opportunity.
avatar
Alcides is a Cell Bio graduate, finishing a PhD in Neuroscience. Writes about life sciences, pharma, and biotech.
2020-08-17 10:34

Diabetes is a group of metabolic disorders characterized by increased levels of blood sugar over prolonged periods of time. A condition tightly related to human development - the prevalence of diabetes has risen specially in places with important wealth, industrial, and economic growth.

There are two main types of diabetes: Type 1 (T1D) diabetes, previously referred to as “insulin-dependent diabetes”, constitutes 5.2% of all diagnosed cases in the US. Type 2 (T2D) diabetes is associated with body weight and exercise, and it accounts for 90% of all diabetic patients. In 2019 there were over 463 million diabetic patients worldwide, a number expected to almost double during the next 25 years. In the US only, it is estimated that 10.5 % of the population is living with diabetes.

Novo Nordisk in the expanding market of diabetes care

An increasing number of health organizations are developing programs and driving funds towards health awareness. In the US, the National Institute of Health spends yearly $1 billion in diabetes research alone. Current healthcare spending in diabetes is upwards of $700 billion annually, and with the current epidemiological trends, the expanding market of diabetes care offers a number of opportunities for investors.

The diabetes care drug market ($69.7 billion) is dominated by insulin, as it is needed by all T1D patients and approximately 20% of T2D patients, totaling 100 million people worldwide. Insulin manufacturers hold the vast majority of the diabetes care market.

NovoNordisk (NASDAQ: NVO) - The Danish multinational controls 47% of the global insulin market, and have seen their sales driven up by mid-single digits consistently over the last three years. With a short-lived drop due to the COVID pandemic, NVO share price increased over 30% in the last year. Although their revenue looks flat YoY, their Q2 net income rose 11% over Q2 2019 reaching $1.7 billion.

Their non-insulin drugs seem to be on the right path also. Ozempic, a GLP-1 receptor drug, injected weekly to manage blood sugar levels in T2D, quadrupled in sales since 2018 when it entered the market, reaching $1.78 billion by the end of 2019. Their new oral drug, Rybelsus, has brought $64.5 million in revenue sin approved by FDA at the end of 2019. Also approved by the Japanese Ministry of Health, Labor and Welfare less than a month ago, Rybelsus is the first not injected GLP-1 receptor treatment approved in the US. NVO also holds leading positions in the Obesity and Haemophilia drug markets.

Together with their solid earnings report for Q2 2020, in which NVO announced a semi-annual dividend of $0.78, the company was able to restart their Phase III trials for a Haemophilia treatment. Based on their continued success in the pharmaceutical pipeline, their consistent sales growth, and the robust lineup of current and in-development products, NVO offers an exciting growth opportunity in the expanding market of diabetes care.

Conclusions

Diabetes care market will continue to grow based on the rising prevalence of diabetes and the increasing number of programs in diabetes awareness. NVO hold the leading position in diabetes drug care - 47% of the global insulin market. Non-insulin drugs are driving sales up, novel treatment approved by FDA. NVO has a good growth potential and represents a good risk/reward opportunity.


Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Rate this article

positive
negative
Published On
2020-08-17 10:34

avatar
About the Author
Alcides is a Cell Bio graduate, finishing a PhD in Neuroscience. Writes about life sciences, pharma, and biotech.


buy-coffee
You've read 1 article in the last year
..thank you for supporting us and for visiting our site. Unlike many other sites, The Dog of Wall Street is available for everyone to read. Our focus is to provide great content for free. Do you like what we are doing? Buy us a cup coffee. It is the fuel that keeps us going..

AI-mazing returns: The top 3 AI stocks to invest in now!
Don't miss out on the opportunity to invest in these cutting-edge companies and be a part of the future of AI.
By Staff | 2 weeks ago

Goldman Sachs Trims the Fat with 3,200 Job Cuts
Goldman Sachs is cutting approximately 3,200 jobs from its core banking and trading units.
By Staff | 4 weeks ago

Tilray Q2 Earnings Leave Investors Wanting More
While Tilray has maintained its leading market share in the recreational cannabis market in Canada and the medical cannabis market in Europe, its Q2 earnings, which included a loss per share of -$0.11 and an adjusted loss per share of -$0.06, have left investors questioning the company's future growth prospects.
By Staff | 4 weeks ago

Qualcomm's partnership with Iridium takes connectivity to new heights
Qualcomm's partnership with Iridium brings satellite-based messaging technology to phones, laptops and other devices, providing new opportunities for connectivity in any location.
By Staff | 4 weeks ago

Hologic's Fiscal Q1 2023 Earnings: A Ray of Hope in a Stormy Year
Hologic has managed to achieve impressive financial results in Fiscal Q1 2023.
By Staff | 4 weeks ago

Why Small and Mid-Cap Stocks Deserve Your Attention
Why valuations make small and mid-cap stocks an attractive option in a potential recession.
By Staff | 4 weeks ago

Get Ready for a Bumpy Year
Despite strong job creation numbers, deeper issues lurk beneath the surface as the Federal Reserve's rate hikes and high inflation threaten to derail the economy.
By Staff | 4 weeks ago